How do we create a better model to provide maximum value from the latest advances in in vitro diagnostics? Can the new technologies in dynamic biomarkers, bioinformatics and multi-omics help justify the case for new therapeutic strategies or ease the regulatory and reimbursement pathway? Do they make precision medicine a more viable business model through simplifying how samples are collected, wearables utilized and information disseminated? This panel will look at the newest technologies and how they will fit into the future models of healthcare.

Ability Level: All

Session ID: 21171